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ABSTRACT 
Objective: This study aims to evaluate possible crystalline changes that can occur with MOX under the influence of temperature and relative 
humidity (RH) as well as to determine the relative solubility of the observed crystalline forms. 
Methods: Thermoanalytical methods with the support of non-thermal analysis such as X-ray powder diffraction and infrared spectroscopy were 
used for testing structural changes of Moxifloxacin hydrochloride (MOX) stored under four different conditions. Additionally, relative solubilities of 
the observed crystalline forms were determined by the shake-flask method.  
Results: After storage for 1 mo at 0 % relative humidity (RH) and 40 % RH, MOX remained with crystal structure unchanged and shown to have a 
good physical stability at these conditions. However, when the drug was stocked for 1 mo at 90 % RH and 75 %, a hydrated crystalline form was 
identified in both conditions. In the solubility assay, it was observed that the hydrated form is less soluble that initial MOX.  
Conclusion: Pharmacotechnical wet processes are not be recommended for the pharmaceutical production of this drug because solvent granulation 
and drying conditions from processing provides a favorable environment for the transition of crystalline forms. According to DSC, TG, PXRD, HPLC 
and FT-IR results, they showed good correlation with each other and ensure reliable interpretation of solid form stability studies. Moreover, these 
findings suggest that stability studies of a polymorphism associated with the evaluation of relative solubility are essential for a stable formulation 
development and to choose between dry or wet granulation processes. 
Keywords: Moxifloxacin hydrochloride, Crystal form, Thermal Analysis, Non-thermal methods, Shake-Flask.  
 
INTRODUCTION 
The global pharmaceutical market has shown continued growth 
over the past 10 y, mainly due to the emergence of new drugs. 
Regulatory agencies, such as Food and Drug Administration (FDA) 
[1] and Brazil’s National Health Surveillance Agency (ANVISA) [2], 
concerned with the therapeutic performance of these new 
formulations, developed regulatory procedures to submit the drug 
under the influence of a variety of environmental factors such as 
temperature and humidity. The studies of a drug kept under 
different conditions provide additional information on its stability 
and structural changes [3-5]. The reasons for determining the 
stability of a drug are based on public health concern, since the loss 
of stability can lead to the formation of degradation products that 
may cause toxicity to the patient [6] or even cause a polymorphic 
transition of the drug. 
The existence of several solid forms of active pharmaceutical 
ingredients (APIs) is a very important topic in the pharmaceutical 
solids, in which crystalline compounds have the capability to exist in 
multiple crystalline architectures and it is associated with distinct 
crystal arrangements of the molecules in the three-dimensional space 
[7]. Crystalline forms include hydrates/solvates, salts, co-crystals and 
polymorphs, and different crystalline forms can be observed in 
processes involving solvents, attrition during the drug formulation, 
wet granulation or phase transition induced by stress conditions [8-
10]. Different solid forms often exhibit distinct chemical and physical 
properties such as melting point, stability, photosensitivity, solubility 
and dissolution rate, which can influence in its pharmacological 
activity [11-13]. Among all solid-state properties of a drug, solubility is 
directly related to its bioavailability.  
Therefore, solubility studies showed great emphasis in recent years, 
and its importance can be seen by the publication of ANVISA 
resolution RDC number 31 declaring obligatory these studies by 
pharmaceutical companies [14]. 
Accordingly, it is essential to conduct screening, characterization 
and control of solid forms in APIs as early as possible during the 
development of the new drug, since about 80 percent (%) of 
pharmaceutical formulations are found in solid forms. In this 
context, typical structure-sensitive analytical techniques are 
important tools in the study of crystalline forms of drugs.  
Powder X-ray diffraction (PXRD) is a widely applied technique in 
these studies because changes in the diffraction pattern can be 
indicative of crystalline changes since the technique is able to detect 
the properties of the crystalline drug lattice. Infrared spectroscopy 
(IR) is helpful for solid-state information of drugs since this 
technique can provide information on the structure and molecular 
conformation of the solid and detection of hydration/dehydration 
processes [7, 15]. Thermoanalytical methods have been used more 
recently for the evaluation of polymorphic systems, which allow 
obtaining information such as purity, melting/transition point and 
enthalpy [16-19]. In addition, the main advantage of these methods 
is a short time of analysis in comparison with other techniques.  
Moxifloxacin hydrochloride (MOX) is a fourth generation synthetic 
fluoroquinolone antibacterial agent. This medication generally is 
prescribed to the patient in high doses (about 400 mg daily). Several 
crystalline forms of MOX are described, which were designated as 
“Form I” (anhydrous) [20]“Form II” (monohydrate) [20], “Form III” 
(anhydrous) [21], “Form IV” [22], “Form A” [23], “Form B” [23], 
“Form C” [24], “Form X” [25], and “Form Y” [25]. Besides these 
forms, there is a stable monohydrate form, which did not name [26, 
27]. Therefore, it is important to monitor and to investigate the 
transition of crystalline forms of MOX, which can affect the 
bioavailability and effective clinical use of solid formulations. Thus, 
the aims of the present study are to evaluate possible crystalline 
changes that can occur with MOX under the influence of temperature 
and relative humidity (RH) as well as to determine the relative 
solubility of the observed crystalline forms.  
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MATERIALS AND METHODS 
MOX was acquired from Dr. ReddysTM, India. Silica gel, sodium 
dichromate (SynthTM, Diadema, São Paulo, Brazil), sodium oxalate 
(VetecTM, Rio de Janeiro, Rio de Janeiro, Brazil) and sodium chloride 
(VetecTM, Rio de Janeiro, Rio de Janeiro, Brazil) were used to conduct 
the stability study. Methanol high performance liquid 
chromatography (HPLC) grade (VetecTM, Duque de Caxias, Rio de 
Janeiro, Brazil), tetrabutylammonium hydrogen sulphate (Sigma-
AldrichTM, Saint Louis, Missouri, USA), phosphoric acid (VetecTM, 
Duque de Caxias, Rio de Janeiro, Brazil), anhydrous sodium sulphite 
(VetecTM, Duque de Caxias, Rio de Janeiro, Brazil), potassium 
dihydrogen phosphate (Jand QuímicaTM, São Paulo, São Paulo, 
Brazil), Polytetrafluoroethylene (PTFE) hydrophilic filters 13 mm 
diameter and 0.50 µm porosity (Advantec MSFTM, Dublin, California, 
USA) and deionized water obtained by using a MilliporeTM Direct-Q 
5TM water purification system (MilliporeTM, Billerica, Massachusett, 
USA) were used to prepare mobile phase for HPLC analysis. Other 
reagents employed were of analytical grade and used without 
further purification.  
Stability study 
The measurements were performed on initial sample of MOX and on 
following samples: stored at 0 % RH (silica gel/20 °C), 40 % RH 
(saturated solution of Na2Cr2O7.2H2O/20 °C), 90 % RH (saturated 
solution of Na2C2O4/20 °C) and 75 % RH (saturated solution of 
NaCl/40 °C). 
Thermogravimetry (TG) 
A TG curve was obtained employing a SII Nanotechnology IncTM. 
(Tokyo, Japan) model EXSTAR TG/DTA7300TM thermo-balance in 
the temperature range of 30 to 600 °C, using opened aluminum 
crucibles and weighing approximately 4 mg of sample, under a 
dynamic dry N2 atmosphere (50 ml/min) and at a heating rate of 10 
°C/min. The TG instrument was first calibrated using indium 
(156.6±0.3 °C and heat of fusion of 28.58±0.3 J/g) and standard 
weights under the same conditions as the samples. 
Differential scanning calorimetry (DSC) 
DSC experiments were conducted using a high-sensitivity DSC 
calorimeter (model EXSTAR DSC7020TM, SII Nanotechnology Inc. TM, 
Tokyo, Japan). Samples (approximately 4 mg) were encapsulated in 
hermetically sealed aluminum pans. All experiments were 
performed under a nitrogen purge gas of 50 ml/min and at a heating 
rate of 10 °C/min, in a temperature range from 30 to 300 °C. An 
Indium standard with purity more than 99.99 % was used for 
calibrating the temperature. 
PXRD analysis 
Diffractograms were obtained in a Powder X-ray diffractometer (model 
Ultima IVTM, RigakuTM, Japan), using a CuKα tube (1.5418 Å), the voltage 
of 40 kV and current of 30 mA, in the range of 5 to 55 ( °2θ).  
IR analysis 
IR spectra were recorded on a Fourier Transform (FT) IR 
Spectrophotometer ShimadzuTM (Tokyo, Japan), model IR Affinity-
1TM, equipped with MIRacleTM attenuated total reflectance (ATR) 
(Pike Technologies, USA). After recording a background spectrum, 
the samples were placed on the zinc selenide (ZnSe) crystal. In each 
sample, 32 scans were recorded with resolution of 2 cm-1
The quantification of MOX in each stored condition was performed 
using an HPLC method according to its monograph at European 
Pharmacopeia [28]. Sample solutions (0.05 mg/ml of MOX) were 
prepared by dilution of 5 mg of MOX in solution A composed of 0.5 
g/l of tetrabutylammonium hydrogen sulphate, 1.0 g/l of potassium 
dihydrogen phosphate, 0.2 % v/v of phosphoric acid and 0.5 g/lof 
anhydrous sodium sulphite. The solutions were then sonicated for 
10 min and filtered through 0.5 µm filters before the HPLC analysis. 




TM, Kyoto, Japan) series LC-10A, consisting of LC-
10ADVP pump, DGU-14A degasser, 7725i manual injector with a 
20 μl loop (RheodyneTM, Rohnert Park, California, USA), CTO-10AVP 
column oven, SPD-10AVP integrated UV detector, SCL-10 AVP 
controller and CLASS-VP 5.02 integration system software. Briefly, 
the pharmacopeial method involves an isocratic elution with the 
column Eclipse XDBTM (AgilentTM, USA) (Phenyl, 5 μm, 4.6 mm x 250 
mm) at 45 °C and the mobile phase of 28 volumes of methanol and 
72 volumes of a solution containing 0.5 g/l of tetrabutylammonium 
hydrogen sulphate, 1.0 g/l of potassium dihydrogen phosphate and 
3.4 g/l of phosphoric acid. The injection volume was 20 μl, the flow 
rate was 1.3 ml/min and spectrophotometric detection at 293 nm. 
Relative solubility determinations by Shake-flask method 
Samples of initial MOX and samples under 90 % RH at 20±0.5 °C 
were added in excess (approximately 30 mg) to 2 ml Eppendorf 
tubes containing 500 µl of Milli-Q water. The tubes (triplicate 
samples) were placed on a shaker table (Solab, SL 180 DTTM, 
Piracicaba, São Paulo, Brazil) and were shaken at 150 rpm for 24 h 
at room temperature. After the shaking period, the suspensions 
were filtered through a 0.50 µm PTFE hydrophilic filter and the 
filtrate was adequately diluted and quantified by the HPLC method 
previously described.  
RESULTS AND DISCUSSION 
DSC curves of initial MOX, as well as samples stored for 1 mo at 0 % 
RH and 40 % RH on 20 °C, are illustrated in fig. 1. The thermal 
profile of the initial MOX displays one sharp endothermic peak at 
256.7 °C (Tonset = 255.13 °C and ∆Hfus 
 
Fig. 1: DSC curve of MOX at initial time and MOX stored for 1 mo 
at 0 % RH/20 °C, 40 % RH/20 °C, 90 % RH/20 °C and 75 % 
RH/40 °C 
 
= 139 J/g) coming from the 
drug melting followed by its decomposition. This profile is 
characteristic of a MOX crystalline substance described by Rao et al. 
[24]. The samples of stored MOX at 20 °C in 0 % RH and 40 % RH 
showed the peak profiles and the thermal parameters such as heat 
of fusion and melting point (onset) similar for the initial sample, 
showing that they do not change significantly during the storage. 
DSC curves of the samples stocked for 1 mo at 90 % RH in 20 °C and 
75 % RH at 40 °C are also represented in fig. 1. Only observing the 
curve profile of MOX exposed at 90 % RH in 20 °C is evident the 
appearance of a new endothermic peak, which was possibly caused 
by the humidity of the environment where it was packaged. In 
addition, occurred the displacement of the second endothermic 
event and the enlargement of the peak. The curve profile of MOX 
stored in the condition of 75 % RH and 40 °C showed an alteration in 
the second endothermic peak with displacement and peak 
broadening, as observed with the MOX stored at 90 % RH and 20 °C.  
 
Table 1 presents the changes in thermal parameters of the samples 
stocked in the conditions mentioned above in comparison with the 
initial MOX. By employing the analysis of variance (Scot-Knott), it is 
possible to establish that there was an alteration with the enthalpies 
of the drug. 
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Table 1: Initial thermal parameters and HPLC results as well as after 1 mo of storage at 20 °C in 90 % RH and 40 °C at 75 % RH for MOX 
Sample HPLC Content average 
±standard deviation (%) 
DSC TG 
Mass loss (%) ΔH average ±standard 
deviation (J/g) 
Onset average ±standard 
deviation (°C) 
Initial MOX 100.0 139.0±1.0 255.0±2.0 3.2 
MOX stored at 90 % RH/20 °C 57.1*±0.6 66.5±0.3 251.0±3.0 41.3 
MOX stored at 75 % RH/40 °C 94.1*±0.8 86.0±1.0 247.0±3.0 4.2 
* These values were obtained by comparison of samples peak areas with initial MOX 
 
The TG curves of MOX showed one principal mass loss event in the 
range of 228.3 °C to 360.9 °C with the loss of 36.3 % resulting to the 
decomposition of the API (fig. 2). The TG analysis of the samples 
storage for 1 mo at 20 °C in 0 % RH and 40 % RH revealed no 
changes in the thermal parameters of the analyzed compound. 
Hence, the thermal analysis proved the stability of MOX after 1 mo of 
storage in these conditions. For samples after 1 mo of storage in 90 
% RH at 20 °C and in 75 % RH at 40 °C, TG curves exhibited changes 
in the profile in comparison with the initial MOX (fig. 2) and it is 
possible to visualize the appearance of an initial mass loss of the 
drug, probably related to the loss of water molecules that were 
incorporated into the structure of MOX due to its exposure to the 
humid environment. In both samples (90 % RH and 75 % RH), the 
second mass loss did not change. 
 
 
Fig. 2: TG curve of MOX stored for 1 mo at 75 % RH/40 °C (a), 
the initial sample of MOX (b) and the stored sample for 1 mo at 
90 % RH/20 °C (c) 
 
The fig. 3 illustrated the PXRD patterns of the initial MOX and samples 
stored for 1 mo at 20 °C in 0 % RH and 40 % RH. As can be observed in 
fig. 3, the PXRD profile of MOX exhibits a typical crystalline diffraction 
pattern, with a sharp main peak at 8.5° 2θ and secondary peaks at 7.1, 
10.2, 17.7, and 21.5° 2θ. The PXRD analysis of the initial MOX reveals 
that the observed peaks of this sample match to the experimental ones 
of the anhydrous substance described as “form C” by Rao et al. [24]. 
The PXRD patterns of the stored MOX samples under 0 % RH and 40 
% RH at 20 °C are also compared in fig. 3. There were not any visible 
changes between powder diffractograms of the initial MOX and the 
sample stored at these different conditions, confirming the thermal 
results.  The fig. 4 illustrated the PXRD patterns of MOX storage at 20 
°C in 90 % RH and at 40 °C in 75 % RH. In both stocked MOX occurred 
the same alterations compared from the initial sample of the drug. 
First distinguishable diffraction peaks appeared at 11.2, 20.4 and 23.6° 
2θ. Additionally, there was lack of the peak at 7.1 ° 2θ and the unique 
peak which remains unchanged in the stored samples was at 5.8 ° 2θ 
in comparison with the initial sample. The most representative 
diffraction peaks at 8.5 and 10.2 ° 2θ of initial MOX were displaced in 
diffractograms of samples stored under these conditions. 
A significant increase in the intensity of peaks at 14.5 and 27.5° 2θ 
was also observed. The experimental PXRD patterns of MOX at 20 °C 
in 90 % RH and 75 % RH at 40 °C are matched to the hydrated “form 
II”, which was described in a patent by Greenberg et al. [20]The 
results are shown in table 2. 
 
Fig. 3: PXRD patterns of the initial MOX and samples stored for 
1 mo at 20 °C in 0 % RH and 40 % RH 
 
Therefore, these results demonstrate that the storage conditions 
under high humidity have substantial influence on the MOX stability, 
contributing to the occurrence of the crystalline form transition of 
anhydrous MOX to the hydrate form. As already reported in the 
literature, the humidity causes significant effects on drugs if there 
are reactive species in the formulation being decisive in the physical 
or chemical modification (such as hydrolysis or hydrate formation) 
[29]. In order to predict the hydrate stability through the induction 
of the loss of water incorporated, we performed a heating using the 
TG by raising the temperature to 200 °C. Thus, the diffractogram 
provided the same major peaks (5.8, 8.4, 10.0, 11.2, 14.5, 20.4, 23.6, 
27.5 degrees 2θ) of hydrated form before heating, occurring only the 
decrease in the intensity of the peaks. Thus, it was concluded that 
the hydrate form is stable and even with the heat is unable to return 
in its original form. 
 
 
Fig. 4: PXRD patterns of the initial MOX and samples stored for 
1 mo at 20 °C in 90 % RH and 40 °C in 75 % RH 
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Table 2: PXRD peaks (Positions in 2θ) from hydrate “form II” 
reported in the literature [20] and from MOX hydrate obtained 
after storage for 1 mo at 90 % RH/20 °C and at 75 %/40 °C) 
Hydrate “form II” described in the 
literature [20](2 Theta) 
Hydrate obtained after 



































The IR spectra corroborated with the results obtained by the other 
techniques. There were not any visible changes in IR spectra of the 
initial sample and the sample stored at the temperature 20 °C in 0 % 
RH and 40 % RH. The most important changes occurred for the 
samples stored at 90 % RH and 75 % RH, as illustrated in fig. 5. One of 
the detected changes occurred in the region of O–H stretching 
vibrations involved in the hydrogen bonds region from approximately 
3600-3150 cm-1. The other alteration occurred in the 1705 cm-1
 
, region 
of C=O stretching vibrations. These spectral variations can be 
attributed to the hydration of MOX due to its exposure at high 
humidity, as observed in the previously demonstrated results. 
 
Fig. 5: IR spectra of the initial MOX and these stored for 1 mo at 
90% RH/20 °C and 75 % RH/40 °C 
As a final evaluation of this stability study, the samples that have 
displayed differences in its crystal lattice (exposed for one month at 
20 °C in 90 % RH and at 40 °C in 75 % RH) were analyzed (triplicate 
samples) by the HPLC method for MOX assay [28]. This HPLC 
method for the quantification of MOX is important because it is 
possible to conclude if occurred the drug degradation, or if really 
happened the appearance of another crystalline form. The 
representative chromatograms obtained from the initial MOX and 
the samples stored under stress conditions are illustrated in fig. 6. 
The initial MOX showed retention time of 12.24 min approximately, 
and the area obtained from this analysis was considered as 100 % in 
order to compare the content with the stored samples. In this 
analysis, no alteration in the chromatographic profile and in the time 
retention of both samples were observed and there were no peaks 
from degradation products, evidencing that is the same substance, 
but in another crystalline form. As can be seen in table 1 the API´s 
storage under the stress conditions showed a reduction in its 
concentration, which is justified by the presence of water in the 
structure of the hydrates as observed in thermogravimetric analysis. 
 
 
Fig. 6: Representative HPLC chromatograms of: initial sample 
of MOX (a), MOX after 1 mo at 75 % RH/40 °C (b) and 90 % 
RH/20 °C (c) 
 
As previously mentioned in the literature, the improper solubility of 
a drug can cause damage in its bioavailability or give rise to large 
fluctuations in the fraction absorbed in the body fluids [30-32]. 
Therefore, it is extremely important to carry out solubility studies in 
drugs that exhibit more than one crystalline form as the case of MOX. 
The shake-flask method was employed to determine the relative 
solubility of the solid forms of MOX. Since both storages for 1 mo (90 
% RH at 20 °C and 75 % RH at 40 °C) provided compounds with the 
same diffractograms, IR spectra, thermal parameters, and retention 
time as shown in the chromatogram, subtends that were obtained 
identical hydrates. Therefore, only the sample stored in 90 % RH at 
20 °C was selected to perform the shake-flask assay.  
The theoretical solubility value of the MOX is 19.6 mg ml-1 as 
describe in the literature [33]. Then, the initial MOX and the sample 
storage under the condition mentioned above were added in excess 
(three times more) in the water to measurement its solubility 
employing the HPLC method for MOX assay [28]. The initial MOX 
showed 23.5 (±0.8) mg/ml of solubility in water. The value was 
slightly higher than expected. On the other hand, the hydrate 
presented as the solubility in water the value of 20.6 (±0.7) mg/ml, 
which was below than the value obtained for the initial form of the 
drug. This difference in solubility was expected, since it is known 
that the solubility of a drug can vary with any change in its physical 
properties, as the crystal form. Moreover, it was observed that the 
hydrate form is less soluble in aqueous media that the 
corresponding anhydrous form (initial MOX), which is also observed 
in most cases of drugs that exhibit anhydrate/hydrate forms [34]. 
Since solubility is related to the drug absorption, the occurrence of 
this crystalline transition can harm the drug therapy. Moreover, 
these data suggest the importance of conducting an investigation of 
these parameters in the early stages of the development of a new 
drug.  
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CONCLUSION 
Even though the storage were varied, only the conditions 90 % 
RH/20 °C and 75 % RH/40 °C have a substantial influence on the 
MOX stability, contributing to the occurrence of the drug crystalline 
form transition, but just one hydrate form of MOX was detected. This 
paper also reported the occurrence of decreased solubility of the 
drug when it transits from initial solid form to the hydrated form. 
Therefore, pharmacotechnical wet processes are not be 
recommended for the pharmaceutical production of this drug 
because solvent granulation and drying conditions from processing 
provides a favorable environment for the transition of crystalline 
forms. 
Different techniques were tested for the evaluation of the solid-state 
stability of MOX, and according to DSC, TG, PXRD, HPLC and FT-IR 
results, they showed good correlation with each other. Among these 
techniques, the thermal analysis proved to be enabled to identify 
and characterize hydrate forms. Furthermore, these methods are a 
powerful tool for a quick screening of structural changes occurring 
during the crystalline form transition and required a minimal 
sample amount and a short time of analysis in comparison with 
other techniques. Moreover, the associations of thermal analysis 
with non-thermal methods (PXRD and IR) ensure reliable 
interpretation of solid form stability studies. 
These findings also suggest that stability studies of polymorphism 
associated with the evaluation of relative solubility are essential for 
a stable formulation development and to choose between dry or wet 
granulation processes. 
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